What VBL Therapeutics does

VBL Therapeutics (Nasdaq: VBLT), legally Vascular Biogenics Ltd. operating as VBL Therapeutics, Inc., is a clinical-stage biopharmaceutical company founded in 2000 by Prof. Dror Harats, M.D. and headquartered in Modi'in, Israel with a U.S. office in Pearl River, NY. The company is pre-revenue with no FDA-approved or commercially marketed products and no NDA submitted; all products are either in pre-clinical research or administered under IND applications in clinical trials. The company is led by a founder-CEO with 200+ peer-reviewed publications and a refreshed board and management team, and has raised over $180M in equity and non-dilutive capital since inception.

The company's core technology is a proprietary Monocyte Targeting Technology (MTT) platform built around the discovery of MOSPD2, a receptor selectively expressed on the surface of monocytes that controls their ability to migrate to inflamed tissues. The lead clinical candidate, VB-601, is an investigational monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and arrests monocyte migration, addressing chronic inflammation via a mechanism distinct from prevailing T-cell and B-cell-targeted anti-inflammatory biologics. VB-601 has shown disease-modifying activity in preclinical models across multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, with a first-in-human Phase 1 study planned for Q1 2023. The company's earlier oncology asset, ofra-vec (VB-111), is a gene-therapy candidate that was in Phase 3 development for ovarian cancer with topline data expected in H2 2022 and was supported by a €17.5M EIC Accelerator award in December 2021.

VBL's business model is currently pre-commercial. There are no marketed products, no product pricing, no commercial distribution channels, and no recurring revenue. Distribution is limited to investigational use under clinical trial protocols. Future revenue, if any, would derive from one-time or recurring drug commercialization sales, licensing royalties, or partnership milestone payments contingent on regulatory approval — none of which has been secured. Stakeholder engagement is conducted via a corporate website (vblrx.com), a dedicated investor relations microsite (ir.vblrx.com), email/phone contact channels for business development and IR, and peer-reviewed scientific publications supporting the MTT platform. The customer base, once a product is approved, would consist of patients with immune-inflammatory diseases, prescribing physicians, and potentially large-pharma partners for licensing or co-development.

Name

VBL Therapeutics

Legal name

Vascular Biogenics Ltd.

Website

https://vblrx.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

VBL Therapeutics (Nasdaq: VBLT) is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases using its proprietary Monocyte Targeting Technology (MTT) platform built around the novel MOSPD2 receptor on monocytes, with lead candidate VB-601 entering Phase 1 in Q1 2023.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Immunology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Clinical-stage biopharmaceuticals
• Monoclonal antibody therapies
• Immune-inflammatory disease treatments
• Monocyte targeting technology
• Investigational oncology therapeutics

Headquarters

HQ city

Or Yehuda

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. None (pre-revenue, clinical-stage): VBL Therapeutics is pre-revenue with no approved products. None of VBL's products have yet been approved for marketing by the U.S. FDA or other foreign regulatory agencies, and no NDA or equivalent has been submitted. Revenue generation is not currently active; future revenue streams would derive from drug commercialization (one-time/recurring sales), licensing royalties, or partnership/milestone payments post-approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

VBL Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases through its proprietary Monocyte Targeting Technology (MTT) platform, which targets the MOSPD2 receptor on monocytes to block their migration into inflamed tissues. Its lead candidate VB-601 is an investigational monoclonal antibody intended for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH and inflammatory bowel disease. The company has no FDA-approved or commercially marketed products and is pre-revenue.

Product overview

VBL Therapeutics operates a single-therapeutic-area pipeline anchored by one proprietary platform, Monocyte Targeting Technology (MTT), rather than a multi-module software platform. The MTT platform — built around the MOSPD2 'mono-walk' receptor on monocytes — generates targeted antibody candidates for chronic immune-inflammatory diseases, and its sole clinical-stage output is the lead candidate VB-601, an investigational anti-MOSPD2 monoclonal antibody in development for multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, with a first-in-human Phase 1 study planned for Q1 2023. The company's earlier oncology asset, ofra-vec (VB-111), was a separate gene-therapy product candidate for ovarian cancer in Phase 3 development through 2021–2022, supported by EIC Accelerator funding. No commercialized products, software modules, or SaaS components are offered; the offering is therefore a platform-plus-lead-asset structure rather than a unified marketed product.

Differentiator

Problem solved

Functional benefit

Products and services

• VB-601 VB-601 is VBL Therapeutics' lead immunology product candidate — an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor on monocytes to block their migration into inflamed tissues. It has shown disease-modifying activity in preclinical models across multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, NASH, and inflammatory bowel disease, and was expected to enter a first-in-human Phase 1 study in Q1 2023.
• Monocyte Targeting Technology (MTT) platform MTT is VBL's proprietary platform technology built around the discovery of the MOSPD2 receptor selectively expressed on the surface of monocytes that controls their ability to migrate to inflamed tissues. VB-601 is the lead candidate emerging from this platform, and MTT underpins VBL's pipeline of targeted antibody therapies for chronic immune-inflammatory diseases.
• ofra-vec (VB-111) ofra-vec (VB-111) is VBL Therapeutics' cancer treatment candidate that was being evaluated in a Phase 3 ovarian cancer clinical trial with topline data expected in the second half of 2022. It received €17.5 million in EIC Accelerator funding (€2.5M grant + €15M equity) in December 2021 to support clinical development and pre-commercialization.

Quantifiable outcome

• VB-601 shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vbltherapeutic
• Facebookfacebook.com/vascularbiogenics
• LinkedInlinkedin.com/company/vascular-biogenics-ltd-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VBL Therapeutics